Protective Effect of Hyperprolactinemia on Oxidative Stress in Patients with Psychotic Disorder on Atypical Antipsychotics Risperidone and Paliperidone: A Cross-Sectional Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Subjects
2.2. Data and Sample Collection
2.3. Prolactin Level Measurement
2.4. Oxidative Stress Measurements
2.5. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Corena-McLeod, M. Comparative pharmacology of risperidone and paliperidone. Drugs R&D 2015, 15, 163–174. [Google Scholar] [CrossRef]
- Stojkovic, M.; Radmanovic, B.; Jovanovic, M.; Janjic, V.; Muric, N.; Ristic, D.I. Risperidone induced hyperprolactinemia: From basic to clinical studies. Front. Psychiatry 2022, 13, 874705. [Google Scholar] [CrossRef] [PubMed]
- Hodkinson, A.; Heneghan, C.; Mahtani, K.R.; Kontopantelis, E.; Panagioti, M. Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: A meta-analysis involving individual participant data and clinical study reports. BMC Med. 2021, 19, 195. [Google Scholar] [CrossRef] [PubMed]
- Stump, T.A.; Nelson, L.A.; Liu, Y.; Kriz, C.R.; Iuppa, C.A.; Diefenderfer, L.A.; Lang, S.E.; Elliot, E.S.; Sommi, R.W. The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection. Ment. Health Clin. 2021, 11, 12–18. [Google Scholar] [CrossRef] [PubMed]
- Carretero, J.; Sánchez-Robledo, V.; Carretero-Hernández, M.; Catalano-Iniesta, L.; García-Barrado, M.J.; Iglesias-Osma, M.C.; Blanco, E.J. Prolactin system in the hippocampus. Cell Tissue Res. 2019, 375, 193–199. [Google Scholar] [CrossRef] [PubMed]
- Marano, R.J.; Ben-Jonathan, N. Minireview: Extrapituitary prolactin: An update on the distribution, regulation, and functions. Mol. Endocrinol. 2014, 28, 622–633. [Google Scholar] [CrossRef] [PubMed]
- Cavaleri, D.; Capogrosso, C.A.; Guzzi, P.; Bernasconi, G.; Re, M.; Misiak, B.; Crocamo, C.; Bartoli, F.; Carra, G. Blood concentrations of anterior pituitary hormones in drug-naive people with first-episode psychosis: A systematic review and meta-analysis. Psychoneuroendocrinology 2023, 158, 106392. [Google Scholar] [CrossRef] [PubMed]
- Bitanihirwe, B.K.; Woo, T.U. Oxidative stress in schizophrenia: An integrated approach. Neurosci. Biobehav. Rev. 2011, 35, 878–893. [Google Scholar] [CrossRef] [PubMed]
- Collin, F. Chemical basis of reactive oxygen species reactivity and involvement in neurodegenerative diseases. Int. J. Mol. Sci. 2019, 20, 2407. [Google Scholar] [CrossRef]
- Dakhale, G.; Khanzode, S.; Khanzode, S.; Saoji, A.; Khobragade, L.; Turankar, A. Oxidative damage and schizophrenia: The potential benefit by atypical antipsychotics. Neuropsychobiology 2004, 49, 205–209. [Google Scholar] [CrossRef]
- Al-Amin, M.M.; Jain, P.; Kazi, M.; Alkholief, M.; Reza, H.M. Pretreatment with risperidone ameliorates systemic LPS-induced oxidative stress in the cortex and hippocampus. Front. Neurosci. 2018, 12, 345659. [Google Scholar] [CrossRef] [PubMed]
- Kajero, J.A.; Seedat, S.; Ohaeri, J.; Akindele, A.; Aina, O. Effects of cannabidiol on vacuous chewing movements, plasma glucose and oxidative stress indices in rats administered high dose risperidone. Sci. Rep. 2022, 12, 19718. [Google Scholar] [CrossRef] [PubMed]
- Cidade-Rodrigues, C.; Cunha, F.M.; Chaves, C.; Silva-Vieira, M.; Silva, A.; Garrido, S.; Martinho, M.; Almeida, M. The utility of prolactin serial sampling and the best prolactin cut-offs associated with persistent hyperprolactinemia. Porto Biomed. J. 2021, 6, e133. [Google Scholar] [CrossRef] [PubMed]
- Ohkawa, H.; Ohishi, N.; Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95, 351–358. [Google Scholar] [CrossRef] [PubMed]
- Pick, E.; Keisari, Y. A simple colorimetric method for the measurement of hydrogen peroxide by cells in culture. J. Immunol. Methods 1980, 38, 161–170. [Google Scholar] [CrossRef] [PubMed]
- Green, L.C.; Wagner, D.A.; Glogowski, J.; Skipper, P.L.; Wishnok, J.S.; Tannenbaum, S.R. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal. Biochem. 1982, 126, 131–138. [Google Scholar] [CrossRef] [PubMed]
- Auclair, C.; Voisin, E. Nitroblue tetrazolium reduction. In Handbook of Methods for Oxygen Radical Research; Greenwald, R.A., Ed.; CRC Press: Boca Raton, FL, USA, 1985; pp. 123–132. [Google Scholar]
- McCord, J.M.; Fridovich, I. Superoxide dismutase: An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem. 1969, 244, 6049–6055. [Google Scholar] [CrossRef] [PubMed]
- Aebi, H. Catalase in vitro. Methods Enzymol. 1984, 105, 121–126. [Google Scholar] [CrossRef] [PubMed]
- Goldberg, I.; Hochman, A. Purification and characterization of a novel type of catalase from the bacterium Klebsiella pneumoniae. Biochim. Biophys. Acta (BBA)-Gen. Subj. 1989, 991, 330–336. [Google Scholar] [CrossRef]
- Beutler, E. A Manual of Biochemical Methods; Grune & Stratton: New York, NY, USA, 1975. [Google Scholar]
- Rajkumar, R.P. Prolactin and psychopathology in schizophrenia: A literature review and reappraisal. Schizophr. Res. Treat. 2014, 2014, 175360. [Google Scholar] [CrossRef]
- Ivanova, S.A.; Osmanova, D.Z.; Boiko, A.S.; Pozhidaev, I.V.; Freidin, M.B.; Fedorenko, O.Y.; Semke, A.V.; Bokhan, N.A.; Kornetova, E.G.; Rakhmazova, L.D.; et al. Prolactin gene polymorphism (−1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. Schizophr. Res. 2017, 182, 110–114. [Google Scholar] [CrossRef] [PubMed]
- Riecher-Rössler, A.; Rybakowski, J.K.; Pflueger, M.O.; Kahn, R.S.; Malik, P.; Fleischhacker, W.W.; EUFEST Study Group. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychol. Med. 2013, 43, 2571–2582. [Google Scholar] [CrossRef] [PubMed]
- Ittig, S.; Studerus, E.; Heitz, U.; Menghini-Müller, S.; Beck, K.; Egloff, L.; Leanza, L.; Andreou, C.; Riecher-Rössler, A. Sex differences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in women. Schizophr. Res. 2017, 189, 111–116. [Google Scholar] [CrossRef] [PubMed]
- Rivero-Segura, N.A.; Flores-Soto, E.; García de la Cadena, S.; Coronado-Mares, I.; Gomez-Verjan, J.C.; Ferreira, D.G.; Cabrera-Reyes, E.A.; Lopes, L.V.; Massieu, L.; Cerbón, M. Prolactin-induced neuroprotection against glutamate excitotoxicity is mediated by the reduction of [Ca2+]i overload and NF-κB activation. PLoS ONE 2017, 12, e0176910. [Google Scholar] [CrossRef] [PubMed]
- García, R.M.; Zamarripa, D.A.; Arnold, E.; Ruiz-Herrera, X.; Imm, R.N.; Cruz, G.B.; Adán, N.; Binart, N.; Riesgo-Escovar, J.; Goffin, V.; et al. Prolactin protects retinal pigment epithelium by inhibiting sirtuin 2-dependent cell death. eBioMedicine 2016, 7, 35–49. [Google Scholar] [CrossRef] [PubMed]
- Ramos-Martinez, E.; Ramos-Martínez, I.; Molina-Salinas, G.; Zepeda-Ruiz, W.A.; Cerbon, M. The role of prolactin in central nervous system inflammation. Rev. Neurosci. 2021, 32, 323–340. [Google Scholar] [CrossRef] [PubMed]
- Yang, R.; Zhang, S.; Duan, C.; Guo, Y.; Shan, X.; Zhang, X.; Yue, S.; Zhang, Y.; Liu, Y. Effect of prolactin on cytotoxicity and oxidative stress in ovine ovarian granulosa cells. PeerJ 2023, 11, e15629. [Google Scholar] [CrossRef] [PubMed]
- Burton, G.J.; Jauniaux, E. Oxidative stress. Best Pract. Res. Clin. Obstet. Gynecol. 2011, 25, 287–299. [Google Scholar] [CrossRef]
- Thébault, S. Potential mechanisms behind the antioxidant actions of prolactin in the retina. Exp. Eye Res. 2017, 160, 56–61. [Google Scholar] [CrossRef]
- Kojer, K.; Riemer, J. Balancing oxidative protein folding: The influences of reducing pathways on disulfide bond formation. Biochim. Biophys. Acta (BBA)-Proteins Proteom. 2014, 1844, 1383–1390. [Google Scholar] [CrossRef]
- Janero, D.R. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic. Biol. Med. 1990, 9, 515–540. [Google Scholar] [CrossRef] [PubMed]
- Flatow, J.; Buckley, P.; Miller, B.J. Meta-analysis of oxidative stress in schizophrenia. Biol. Psychiatry 2013, 74, 400–409. [Google Scholar] [CrossRef] [PubMed]
- Raffa, M.; Atig, F.; Mhalla, A.; Kerkeni, A.; Mechri, A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 2011, 11, 124. [Google Scholar] [CrossRef] [PubMed]
- De Simone, G.; Mazza, B.; Vellucci, L.; Barone, A.; Ciccarelli, M.; de Bartolomeis, A. Schizophrenia synaptic pathology and antipsychotic treatment in the framework of oxidative and mitochondrial dysfunction: Translational highlights for the clinics and treatment. Antioxidants 2023, 12, 975. [Google Scholar] [CrossRef] [PubMed]
- Ribaudo, G.; Bortoli, M.; Pavan, C.; Zagotto, G.; Orian, L. Antioxidant potential of psychotropic drugs: From clinical evidence to in vitro and in vivo assessment and toward a new challenge for in silico molecular design. Antioxidants 2020, 9, 714. [Google Scholar] [CrossRef] [PubMed]
- Caruso, G.; Grasso, M.; Fidilio, A.; Tascedda, F.; Drago, F.; Caraci, F. Antioxidant properties of second-generation antipsychotics: Focus on microglia. Pharmaceuticals 2020, 13, 457. [Google Scholar] [CrossRef]
- Cui, H.; Kong, Y.; Zhang, H. Oxidative stress, mitochondrial dysfunction, and aging. J. Signal Transduct. 2012, 2012, 646354. [Google Scholar] [CrossRef]
Variable | Group | Data | Statistics; p Value |
---|---|---|---|
Total number | 155 | ||
Sex (n (%)) | Male | 101 (65.2%) | |
Female | 54 (34.2%) | ||
Age (M ± SD) | 41.7 ± 11.9 years | ||
Age by sex (M ± SD) | Male | 39.5 ± 11.4 | t = −3.190, p = 0.002 |
Female | 45.7 ± 11.9 | ||
PRL level (M ± SD) | 27.41 ± 19.70 ng/mL | ||
PRL level by sex (M ± SD) | Male | 19.33 ± 11.01 | t = −6.914, p < 0.001 |
Female | 42.21 ± 23.28 | ||
Number of patients by PRL group (n (%)) | Normal PRL | 85 (54.8%) | |
Asymptomatic HPRL | 37 (23.9%) | ||
Symptomatic HPRL | 33 (21.3%) | ||
PRL level by PRL group (M ± SD) | Normal PRL | 14.08 ± 6.00 ng/mL | F = 142.559; p < 0.001 |
Asymptomatic HPRL | 38.18 ± 11.78 ng/mL | ||
Symptomatic HPRL | 53.01 ± 19.97 ng/mL | ||
Age by PRL group (M ± SD) | Normal PRL | 40.3 ± 11.4 years | F = 1.367; p = 0.258 |
Asymptomatic HPRL | 42.6 ± 12.8 years | ||
Symptomatic HPRL | 44.1 ± 12.1 years | ||
Number of patients by drug form (n (%)) | Oral risperidone | 51 (32.9%) | |
LAI-R | 29 (18.7%) | ||
LAI-Pm | 33 (21.3%) | ||
LAI-Pq | 42 (27.1%) | ||
Age by drug form (M ± SD) | Oral risperidone | 41.16 ± 1.8 years | F = 0.099; p = 0.961 |
LAI-R | 42.25 ± 2.8 years | ||
LAI-Pm | 42.18 ± 2.0 years | ||
LAI-Pq | 41.38 ± 1.8 years | ||
Duration of therapy (n (%)) | Under 6 months | 42 (27.1%) | |
6–12 months | 25 (16.1%) | ||
Over 12 months | 88 (56.8%) | ||
Age by duration of therapy (M ± SD) | Under 6 months | 38.26 ± 12.8years | F = 6.210; p = 0.003 |
6–12 months | 37.33 ± 11.4years | ||
Over 12 months | 44.50 ± 10.9 years |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Stojkovic, M.; Jovanovic, M.; Jakovljevic, V.; Zivkovic, V.; Djordjevic, N.; Kocovic, A.; Nikolic, M.; Stojanovic, A.; Minic, N.; Ignjatovic, V.; et al. Protective Effect of Hyperprolactinemia on Oxidative Stress in Patients with Psychotic Disorder on Atypical Antipsychotics Risperidone and Paliperidone: A Cross-Sectional Study. Biomedicines 2024, 12, 1418. https://doi.org/10.3390/biomedicines12071418
Stojkovic M, Jovanovic M, Jakovljevic V, Zivkovic V, Djordjevic N, Kocovic A, Nikolic M, Stojanovic A, Minic N, Ignjatovic V, et al. Protective Effect of Hyperprolactinemia on Oxidative Stress in Patients with Psychotic Disorder on Atypical Antipsychotics Risperidone and Paliperidone: A Cross-Sectional Study. Biomedicines. 2024; 12(7):1418. https://doi.org/10.3390/biomedicines12071418
Chicago/Turabian StyleStojkovic, Milena, Mirjana Jovanovic, Vladimir Jakovljevic, Vladimir Zivkovic, Natasa Djordjevic, Aleksandar Kocovic, Marina Nikolic, Aleksandra Stojanovic, Natasa Minic, Vesna Ignjatovic, and et al. 2024. "Protective Effect of Hyperprolactinemia on Oxidative Stress in Patients with Psychotic Disorder on Atypical Antipsychotics Risperidone and Paliperidone: A Cross-Sectional Study" Biomedicines 12, no. 7: 1418. https://doi.org/10.3390/biomedicines12071418